UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 142

Sortiert nach

PET imaging in prostate cancer: focus on prostate-specific membrane antigen

Current topics in medicinal chemistry, 2013, Vol.13 (8), p.951

2013

Volltextzugriff (PDF)

2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer

Clinical cancer research, 2011-12, Vol.17 (24), p.7645-7653

2011

Volltextzugriff (PDF)

Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

Molecular imaging and biology, 2015-08, Vol.17 (4), p.565-574

2015

Volltextzugriff (PDF)

Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules

Journal of medicinal chemistry, 2021-04, Vol.64 (7), p.4059-4070

2021

Volltextzugriff (PDF)

Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide

Molecular imaging, 2019-01, Vol.18, p.1536012119852189-1536012119852189

2019

Volltextzugriff (PDF)

Radionuclide based imaging of prostate cancer

Current topics in medicinal chemistry, 2010-11, Vol.10 (16), p.1600

Mease, Ronnie C

2010

Volltextzugriff (PDF)

A low molecular weight PSMA-based fluorescent imaging agent for cancer

Biochemical and biophysical research communications, 2009-12, Vol.390 (3), p.624-629

2009

Volltextzugriff (PDF)

Synthesis and Biological Evaluation of Low Molecular Weight Fluorescent Imaging Agents for the Prostate-Specific Membrane Antigen

Bioconjugate chemistry, 2012-12, Vol.23 (12), p.2377-2385

2012

Volltextzugriff (PDF)

Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)

Journal of medicinal chemistry, 2008-08, Vol.51 (15), p.4504-4517

2008

Volltextzugriff (PDF)

Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer

Journal of medicinal chemistry, 2008-12, Vol.51 (24), p.7933-7943

2008

Volltextzugriff (PDF)

An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [18F]DCFPyL

Journal of labelled compounds & radiopharmaceuticals, 2016-09, Vol.59 (11), p.439-450

2016

Volltextzugriff (PDF)

N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer

Clinical cancer research, 2008-05, Vol.14 (10), p.3036-3043

2008

Volltextzugriff (PDF)

In Vitro and In Vivo Characterization of Dibenzothiophene Derivatives [ 125 I]Iodo-ASEM and [ 18 F]ASEM as Radiotracers of Homo- and Heteromeric α7 Nicotinic Acetylcholine Receptors

Molecules (Basel, Switzerland), 2020-03, Vol.25 (6), p.1425

2020

Volltextzugriff (PDF)

Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer

Clinical cancer research, 2005-06, Vol.11 (11), p.4022-4028

2005

Volltextzugriff (PDF)

A red-shifted fluorescent substrate for aldehyde dehydrogenase

Nature communications, 2014-04, Vol.5 (1), p.3662-3662, Article 3662

2014

Volltextzugriff (PDF)

A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents

Biomolecules (Basel, Switzerland), 2022-03, Vol.12 (3), p.405

2022

Volltextzugriff (PDF)

A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA)

Oncotarget, 2011-12, Vol.2 (12), p.1244-1253

2011

Volltextzugriff (PDF)

An Improved 211 At-Labeled Agent for PSMA-Targeted α-Therapy

Journal of Nuclear Medicine, 2022-02, Vol.63 (2), p.259-267

2022

Volltextzugriff (PDF)

Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen

Journal of Nuclear Medicine, 2015-09, Vol.56 (9), p.1401-1407

2015

Volltextzugriff (PDF)

(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy

Journal of Nuclear Medicine, 2016-10, Vol.57 (10), p.1569-1575

2016

Volltextzugriff (PDF)

PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer

Molecular imaging and biology, 2016-06, Vol.18 (3), p.411-419

2016

Volltextzugriff (PDF)

Dual-Modality PET–SPECT Image-Guided Pretargeting Delivery in HER2(+) Breast Cancer Models

Biomacromolecules, 2021-11, Vol.22 (11), p.4606-4617

2021

Volltextzugriff (PDF)

Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA

Bioconjugate chemistry, 2016-06, Vol.27 (6), p.1447

2016

Volltextzugriff (PDF)

Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer

Journal of medicinal chemistry, 2014-03, Vol.57 (6), p.2657

2014

Volltextzugriff (PDF)

F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer

The Journal of nuclear medicine (1978), 2015-07, Vol.56 (7), p.1003-1010

2015

Volltextzugriff (PDF)

1 – 25 von 142

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(130)
Mit Volltextzugriff
(138)

Publikationsform

Artikel
(141)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Life Sciences & Biomedicine
(56)
Animals
(54)
Humans
(51)
Male
(43)
Mice
(43)
Prostate Cancer
(26)
Tissue Distribution
(26)
Cell Line, Tumor
(24)
Prostatic Neoplasms - Diagnostic Imaging
(19)
Female
(17)
Positron-Emission Tomography
(17)
Radiology, Nuclear Medicine & Medical Imaging
(17)
Biological And Medical Sciences
(16)
Glutamate Carboxypeptidase Ii - Metabolism
(16)
Antigens
(15)
Mice, Scid
(15)
Pharmacology & Pharmacy
(15)
Radiopharmaceuticals - Pharmacokinetics
(15)
Tumors
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PET imaging in prostate cancer: focus on prostate-specific membrane antigen

2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer

Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules

Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide

Radionuclide based imaging of prostate cancer

A low molecular weight PSMA-based fluorescent imaging agent for cancer

Synthesis and Biological Evaluation of Low Molecular Weight Fluorescent Imaging Agents for the Prostate-Specific Membrane Antigen

Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)

Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer

An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [18F]DCFPyL

N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer

In Vitro and In Vivo Characterization of Dibenzothiophene Derivatives [ 125 I]Iodo-ASEM and [ 18 F]ASEM as Radiotracers of Homo- and Heteromeric α7 Nicotinic Acetylcholine Receptors

Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer

A red-shifted fluorescent substrate for aldehyde dehydrogenase

A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents

A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA)

An Improved 211 At-Labeled Agent for PSMA-Targeted α-Therapy

Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen

(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy

PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer

Dual-Modality PET–SPECT Image-Guided Pretargeting Delivery in HER2(+) Breast Cancer Models

Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA

Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer

F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer

Suchergebnisse filtern